Resectable BC categories that receive neoadjuvant therapy according to standard approach (TNBC, HER2+ tumors and ≥cT2 or N+ Estrogen Receptors positive (ER+)/HER2− tumors) can be directed for upfront surgery if the pandemic is not in an escalatory phase with currently available hospital resources that are likely to be occupied in the next weeks/months [26,28,50];. The gene discussed is ERBB2; the disease is breast cancer.